From Financialpost · · 1m 20s
Impulse Dynamics Shows Heart Failure Therapy Benefits
Impulse Dynamics reports one-year heart failure therapy data showing 34% hospitalization reduction.
In brief
Impulse Dynamics reports one-year heart failure therapy data showing 34% hospitalization reduction. Impulse Dynamics' CCM therapy reduced heart failure hospitalizations by 34% at one year for patients already on guideline-directed medical therapy. Originally reported by Financialpost.
Impulse Dynamics Presents Heart Failure Study Results
Impulse Dynamics announced late-breaking one-year clinical outcomes from its U.S. Post-Approval Study of CCM Therapy presented at the Heart Failure Society of America 2026 Annual Scientific Meeting.
Study Includes 530 Patients Across 71 Sites
The Post-Approval Study was a prospective multicenter long-term observational study approved by the FDA evaluating long-term safety and clinical outcomes of CCM Therapy with 530 participants across 71 sites.
34% Heart Failure Hospitalization Reduction
Evidence at one year showed a 34% reduction in heart failure hospitalization for patients already optimized on guideline-directed medical therapy.
97% Improved or Stabilized Functional Class
97% of patients had improved or stabilized NYHA functional class at one year with 68.1% improving by at least one class.
Diuretic Therapy Reduction
Over 35% of patients receiving diuretics at baseline discontinued or decreased diuretic therapy.
NT-proBNP Biomarker Improvement
18.5% decrease in NT-proBNP in patients with elevated baseline levels a key biomarker of heart failure.
Functional Status Improvement
70% of patients achieved at least a 5-point improvement in the Minnesota Living with Heart Failure Questionnaire score.
The main idea
Impulse Dynamics' CCM therapy reduced heart failure hospitalizations by 34% at one year for patients already on guideline-directed medical therapy.
